LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

Home・Aandelen Lijst・AbbVie Inc

AbbVie Inc

Gesloten

SectorGezondheidszorg

216.12 0.45

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

216.04

Max

217.6

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.1B 697M
Verkoop	-1.6B 15B
K/W Sectorgemiddelde	103.158 49.701
EPS	2.65
Dividendrendement	3.2
Winstmarge	4.646
Werknemers	57,000
EBITDA	-635M 4.7B

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+18.32% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	3.20% 2.39%
Volgende Winsten	30 jul 2026
Volgende dividenddatum	14 aug 2026
Volgende Ex Dividend datum	14 jul 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	21B 370B
Vorige openingsprijs	215.67
Vorige sluitingsprijs	216.12

Nieuwssentiment

By Acuity

23%

77%

39 / 345 Rangschikking in Healthcare

AbbVie Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 apr 2026, 12:38 UTC

Winsten

AbbVie Raises Fiscal Year Guidance on Immunology, Neuroscience Growth

4 feb 2026, 13:20 UTC

Winsten

AbbVie 4Q Revenue Rises on Immunology Growth

29 apr 2026, 12:41 UTC

Winsten

AbbVie Beats Earnings Estimates, Boosts 2026 Outlook. What It Means for the Stock. -- Barrons.com

29 apr 2026, 12:23 UTC

Winsten

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

29 apr 2026, 11:50 UTC

Winsten

AbbVie Raising Adjusted EPS Guidance for FY26 >ABBV

29 apr 2026, 11:49 UTC

Winsten

AbbVie 1Q Global Humira Rev $688 M >ABBV

29 apr 2026, 11:48 UTC

Winsten

AbbVie 1Q Global Rinvoq Rev $2.119 B >ABBV

29 apr 2026, 11:47 UTC

Winsten

AbbVie 1Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

29 apr 2026, 11:47 UTC

Winsten

AbbVie 1Q Global Skyrizi Rev $4.48B >ABBV

29 apr 2026, 11:47 UTC

Winsten

AbbVie 1Q Global IMBRUVICA Rev $556M >ABBV

29 apr 2026, 11:47 UTC

Winsten

AbbVie 1Q EPS 39c >ABBV

29 apr 2026, 11:47 UTC

Winsten

AbbVie 1Q Net $695M >ABBV

29 apr 2026, 11:47 UTC

Winsten

AbbVie 1Q International HUMIRA Rev $331M >ABBV

29 apr 2026, 11:47 UTC

Winsten

AbbVie 1Q Rev $15B >ABBV

29 apr 2026, 11:47 UTC

Winsten

AbbVie 1Q Adj EPS $2.65 >ABBV

29 apr 2026, 11:47 UTC

Winsten

AbbVie 1Q U.S. HUMIRA Rev $357M >ABBV

29 apr 2026, 11:47 UTC

Winsten

AbbVie Sees FY Adj EPS $14.08-Adj EPS $14.28 >ABBV

4 feb 2026, 19:38 UTC

Winsten

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 feb 2026, 16:19 UTC

Winsten

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 feb 2026, 15:18 UTC

Winsten

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 feb 2026, 13:18 UTC

Winsten

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 feb 2026, 12:48 UTC

Winsten

AbbVie 4Q U.S. HUMIRA Rev $897M >ABBV

4 feb 2026, 12:48 UTC

Winsten

AbbVie 4Q Rev $16.62B >ABBV

4 feb 2026, 12:48 UTC

Winsten

AbbVie 4Q Global IMBRUVICA Rev $671M >ABBV

4 feb 2026, 12:48 UTC

Winsten

AbbVie 4Q Global Skyrizi Rev $5.01B >ABBV

4 feb 2026, 12:48 UTC

Winsten

AbbVie 4Q Net $1.82B >ABBV

4 feb 2026, 12:48 UTC

Winsten

AbbVie 4Q Adj EPS $2.71 >ABBV

4 feb 2026, 12:48 UTC

Winsten

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.66B >ABBV

4 feb 2026, 12:48 UTC

Winsten

AbbVie 4Q International HUMIRA Rev $349M >ABBV

4 feb 2026, 12:48 UTC

Winsten

AbbVie Sees FY Adj EPS $14.37-Adj EPS $14.57 >ABBV

Peer Vergelijking

Prijswijziging

AbbVie Inc Prognose

Koersdoel

By TipRanks

18.32% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 255.22 USD 18.32%

Hoogste 298 USD

Laagste 203 USD

Gebaseerd op 20 Wall Street-analisten die 12-maands prijsdoelen bieden voor AbbVie Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

20 ratings

Buy

Hold

Sell

Gebaseerd op 20 analisten die aandelenratings hebben gegeven aan AbbVie Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

39 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.